Carrez et al 2025 Figure S1 to S7

We studied the cellular and molecular mechanisms underlying Trikafta's clinical efficacy, by using human bronchial epithelial cells from F508del homozygous patients and human bronchial epithelial CFBE41o- cells expressing F508del-CFTR.

本研究以来自F508del纯合子患者的人支气管上皮细胞，以及表达F508del-CFTR的人支气管上皮CFBE41o-细胞为实验材料，探究了特卡芙塔（Trikafta）临床疗效背后的细胞与分子机制。